Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MMP12 | P39900 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RAF1 | P04049 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490264 | 1.00 | MAPT (0.60) | MAPTPOLBMMP12PARP1ALDH1A1 | |
| SCHEMBL30806805 | 0.88 | POLB (0.51) | MAPTPOLBMMP12PARP1ALDH1A1 | |
| SCHEMBL282326 | 0.88 | POLB (0.51) | MAPTPOLBMMP12PARP1ALDH1A1 | |
| SCHEMBL2062240 | 0.85 | MAPT (0.46) | MAPTPOLBMMP12ALDH1A1SMN1; SMN2 | |
| SCHEMBL2627043 | 0.84 | MAPT (0.46) | MAPTPOLBMMP12ALDH1A1KMT2A | |
| SCHEMBL20086711 | 0.83 | MAPT (0.45) | MAPTPOLBMMP12ALDH1A1KMT2A | |
| SCHEMBL9377316 | 0.82 | CYP3A4 (0.55) | MAPTPOLBALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4263148 | 0.82 | NR3C2 (0.54) | MAPTPOLBMMP12ALDH1A1KMT2A | |
| SCHEMBL13932063 | 0.82 | NR3C2 (0.54) | MAPTPOLBMMP12ALDH1A1KMT2A | |
| SCHEMBL4295502 | 0.79 | MAPT (0.72) | MAPTPOLBPARP1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094941-A | Novel azido formation of 6-hydroxy-benzomorpholine (3, 4-dihydro-2H-1, 4-benzoxazin-6-ol) | — | 2026-05-26 | — | — | CN | claimed |
| WO-2025099111-A1 | NEW TELESCOPING SYNTHESES OF 6-HYDROXY-BENZOMORPHOLINE (3,4-DIHYDRO-2H-1,4-BENZOXAZIN-6-OL) | WELLA GERMANY GMBH (DE) | 2025-05-15 | — | — | WO | claimed |
| CN-103588722-A | Synthetic method of 6-nitro-2H-1, 4-benzoxazine-3(4H)-one | CHINATECH PEPTIDE CO LTD | 2014-02-19 | — | — | CN | claimed |
| CN-122094941-A | Novel azido formation of 6-hydroxy-benzomorpholine (3, 4-dihydro-2H-1, 4-benzoxazin-6-ol) | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2025137303-A1 | META-PHENYLENEDIAMINE ANTIDEGRADANT COMPOUNDS AND USES THEREOF | FLEXSYS AMERICA L.P. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025099111-A1 | NEW TELESCOPING SYNTHESES OF 6-HYDROXY-BENZOMORPHOLINE (3,4-DIHYDRO-2H-1,4-BENZOXAZIN-6-OL) | WELLA GERMANY GMBH (DE) | 2025-05-15 | — | — | WO | disclosed |
| CN-119894878-A | Aromatic amide derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20240424113-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-12-26 | — | — | US | disclosed |
| EP-4419531-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024078569-A1 | AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江海正药业股份有限公司 | 2024-04-18 | — | — | WO | disclosed |
| WO-2023065014-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2023-04-27 | — | — | WO | disclosed |
| EP-0548254-A1 | 6- or 7- (2-IMINO-2-IMIDAZOLIDINE)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN, INC. (US) | 1993-06-30 | — | — | EP | disclosed |
| WO-1992004345-A1 | 6- or 7- (2-IMINO-2-IMIDAZOLIDINE)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS | ALLERGAN, INC. (US) | 1992-03-19 | — | — | WO | disclosed |
| US-5091528-A | Antiglaucoma, antidiarrhea agents, diuretics, vasoconstrictors | ALLERGAN, INC. (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0432893-A2 | Benzoxazine derivatives, their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-06-19 | — | — | EP | disclosed |
| EP-0415641-A1 | Substituted glutaramic acids and derivatives | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
| EP-0415642-A1 | Glutarimides | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
| EP-0263299-B1 | BENZOXAZINES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1990-11-07 | — | — | EP | disclosed |
| US-4804394-A | Benzoxazines and use as herbicides | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-02-14 | — | — | US | disclosed |
| EP-0263299-A1 | Benzoxazines | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1988-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424113-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | MAPT 429/4885POLB 3681/4885MMP12 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.